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Aim: Attempts have been made to use CTC values for interpretation of treatment response and to guide change
of chemotherapy by using a static cut-off of 5 CTC to stratify patients in favourable or unfavourable responders. We
propose anewapproach to interpret treatment effect using significant changes inCTC values (SCV-limits1) as grouping
parameter for responders and non-responders to chemotherapy among metastatic breast cancer (mBC) patients.
Method: CTC were analysed using the CellSearch System in blood from 47 mBC patients before the start of new
chemotherapy and before the third cycle of therapy. The new and old approach to interpret changes in CTC values
were compared in relation to progression free survival (PFS). Results: The new approach using significant CTC change
(P = .032) and the old approach using static cut-off (P N .001) correlated significantly with PFS using a cohort of 47
patients. Conclusion: We propose a new approach to interpret significant changes between baseline and follow-up
CTC values as a tool for assessing treatment effect in mBC. Our approach stratified patients in new risk groups that
were stratified significantly with respect to PFS. More patients are needed to balance the size of the risk groups for
better comparison to the existing approach based on a 5 CTC cut-off.
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1 Significant change value (SCV) limits signify a significant difference between two
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CTC in peripheral blood have repeatedly been shown to have
prognostic value in breast, colorectal, prostate, urothelial, and gastric
cancer [1–6]. The expectations are high when it comes to the use of
CTC as a readily accessible liquid biopsy for monitoring treatment
effect of therapy administration in the clinic [7–10]. It is desirable to
detect an early effect of the treatment so the patient can avoid the loss
of valuable time in effective treatment and severe side effects from an
inefficient treatment. Changes in CTC levels above and below cut-off
values have been compared to clinical imaging of progressive disease
[11]. The treatment effect using CTC is most often monitored as a
baseline value compared to a follow-up value after a given number of
weeks or cycles of therapy [6,10,12–14].
The long awaited randomized, prospective phase III clinical trial,
SWOG S0500, had the primary objective to determine whether mBC
patients with CTC ≥5/7.5 ml after the first follow-up could benefit
from changing to an alternative chemotherapy regime rather than
wait for clinical evidence of progressive disease before changing to an
alternative chemotherapy. Preliminary results showed that the cut-off
of 5 CTC could not guide clinicians in changing chemotherapy basedon the hypothesis that a baseline value ≥5 CTC/7.5 ml blood and a
follow-up value ≥5 CTC indicate a lack of treatment response
[15,16]. The cut-off value of 5 CTC was stated as prognostic for
overall survival (OS) and progression free survival (PFS) by
Cristofanilli et al. in 2004 using the FDA approved CellSearch
System for CTC detection [1,13]. Detecting these extremely rare
CTC among billions of blood cells is technically challenging. The
uncertainty of the CTC analysis value is accordingly high but even
though the issues of CTC rarity have been addressed [5,17,18] the
analytical uncertainty of the CTC result has not been taken into
Table 1. Patient Demographics
Demographic Data Patients
No. %
Age Mean (SD)
[Range]
59.8 (13.2)
[30–81 y]
Metastatic site Liver 10 21
Lung 2 4
Bone 4 9
Subcutaneous 1 2
Lymph 2 4
Two sites 22 47
Multiple sites 6 13
Performance status WHO baseline 0 21 45
1 16 34
2 4 9
Unknown 6 13
Survival Alive 35 74
Mors 12 26
Progression Progression 26 55
Censored 21 45
Line of therapy 1 21 45
2 12 26
3 6 13
4 + 5 + 6 8 17
Type of recidive therapy Endocrine + Trastuzumab 1 2
Chemo 20 43
Chemo + Endocrine 15 32
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value and follow-up CTC value after administration of therapy [15].
Given a baseline sample containing 5 CTC in 7.5 ml blood, a follow-
up value after chemotherapy of 4 CTC could be accepted as a
response to the treatment in the SWOG S0500 trial. This difference
of one CTC between baseline and follow-up CTC values is hampered
by the extreme rarity of the CTC in the blood and the associated lack
of precision in the technology used to detect the CTC [5,17,18].
By taking the uncertainty of the CTC measurement into account,
it is feasible to set up decision limits for a significant change between
baseline and follow-up values of CTC. We suggest that such decision
limits could give the clinicians a more accurate measure of treatment
efficacy and thus spare the patients unnecessary toxicity and loss of
time in ineffective treatment. The hypothesis addressed here was that
a response to chemotherapy can be evaluated as a significant change
between the number of CTC in the baseline and the follow-up
sample. The primary aim of this study was to evaluate an alternative
approach for clinicians to interpret chemotherapy treatment response
based on a significant change in a baseline and a follow-up CTC
value. The significant change was assessed by taking the significant
change value (SCV) limits of the CellSearch System measurement
into account [19].Chemo + Trastuzumab 7 15
Chemo + Endo + Trastu 4 9
ER status (10) ER+ 32 68
ER- 15 32
PgR status (10) PgR+ 18 38
PgR− 21 45
Unknown 8 17
HER2 status (10) HER2+ 11 23
HER2- 27 57
Unknown 9 19
Histology (10) Ductal invasive 46 92
Lobular invasive 2 4
Others 2 4
TNM score (10) T1 8 17
T2 18 38
T3 5 11
T4 9 19
Tx 6 13
Unknown 1 2
N0 10 21
N1 21 45
N2 7 15
N3 5 11
Nx 1 2
Unknown 3 6
M0 (at 10 diagnosis) 33 70
M1 10 21
Mx 2 4
Unknown 2 4
Pt: patients. 10: primary tumour; HER2: human epidermal growth factor receptor 2; ER: estrogen
receptor; PgR: progesterone receptor; Chemo: chemotherapy.Materials and Methods
This study was approved by The National Committee on Health
Research Ethics in Denmark, registered as S20100102. After oral and
printed information, all patients gave written consent for enrolment
in the study at the Department of Oncology, Lillebaelt Hospital,
Vejle, Denmark.
Patients
47 women entered the study cohort consecutively from
November 2012 to December 2013 and in accordance with the
inclusion criteria: Evaluable metastatic breast cancer, WHO
performance status ≤2 and no concomitant inflammatory bowel
disease. Patients were starting up in 1st–6th line of chemotherapy
with or without HER2 targeted trastuzumab, bevacizumab or
lapatinib therapy. Clinical evaluations were conducted in a standard
manner and were blinded for CTC data. TNM score, histology,
human epidermal growth factor receptor 2 (HER2), oestrogen
receptor (ER) and progesterone receptor (PgR) status were evaluated
on the primary disease. ER, PgR were considered positive by
immunohistochemistry (IHC) when N1% of tumour cells were
stained positive. HER2 were evaluated using the Danish Breast
Cancer Cooperative Group (DBCG) criteria (IHC = 0, 1, 2 or 3; if
IHC = 2 FISH should be N2.0 to confirm positive HER2 status).
Progression free Survival (PFS) was measured from the time of the first
baseline sample drawn until the time of the first confirmed suspicion of
disease progression or death. Progression was evaluated according to the
RECIST criteria version 1.1 such as alanine aminotransferase (ALAT)
increase, computer tomography, magnetic resonance, and ultrasound
scan evaluations of the tumour [20]. OS was measured from the time of
the first baseline blood drawn to the time of death by all causes.
Progression and survival data were gathered on 02-02-2014. The
demographic data of the cohort are summarized in Table 1.
Study design
CTC were evaluated in replicate blood samples collected in 9 ml
CellSave tubes at baseline (C1, Table 2) before the start of the firstcycle of a new line of chemotherapy and again in replicate blood
samples before the 3 cycles of chemotherapy (C3, Table 2). The mean
baseline to follow-up time was 6.3 weeks ranging [5.6-8.9].
Evaluation
Treatment effect was evaluated according to the existing approach
based on a cut-off of 5 CTC/7.5ml blood and the new approach
based on significant change value (SCV) limits.
In the existing 5 CTC cut-off approach presented by Cristofanilli
and Hayes et al. [12,13] a change from unfavourable CTC ≥5 at
baseline to favourable CTC b5 at follow-up should improve survival
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696 Treatment Effect in cancer using new CTC approach Horn et al. Translational Oncology Vol. 7, No. 6, 2014and was expected to function as a marker for treatment response. The
following grouping criteria were employed [12]: Group 1: Baseline C1
b5 CTC/7.5 ml and follow-up C3 b5 CTC/7.5 ml; Gr.2: C1 ≥5/C3
b5; Gr.3: C1 b5/C3 ≥5; Gr.4: C1 ≥5/C3 ≥5. Onwards this approach
for evaluating treatment effect is referred to as “Gr1234” (Figure 3).
The proposed alternative approach for evaluation of treatment
effect of chemotherapy will be referred to as “GrABC”. The GrABC
approach was based on a significant change between C1 baseline
CTC value and the follow-up CTC value C3. The significant change
was assessed using a clear and readable difference plot with significant
change value (SCV) limits of the CellSearch System measurements
plotted (Figure 1). The SCV-limits (also known as reference change
values) in the difference plot (Equation 4) were based on the variation
coefficients CV%(dd) of CTC measurements on replicate 7.5 ml
blood samples collected from the same vein puncture of the individual
patients at baseline [19]:
SCV% ¼ Z 2ð Þ1=2  CV% totð Þ ð1Þ
CV% totð Þ ¼ ΣCV% ddð Þ2=n
 1=2
ð2Þ
CV% ddð Þ ¼ 100σ ddð Þ=μ ddð Þ ð3Þ
Z = 1.96 for a 5% two-tailed gaussian distribution μ(dd) is the mean of
the replicate CTCmeasurement of the individual patient’s baseline and
σ(dd) was the standard deviation. SCV were calculated for the baseline
values of CTC in the intervals [N0–4], n = 18; [5–20], n = 8; [20–
13.803], n = 14. Seven patients had mean baseline values equal to zero
and were consequently not evaluable for CV%. The limit values were
estimated as values in CTC units for follow-up value X
SCV Xð Þ ¼ SCV%X=100 ð4Þ
The SCV-limits in the difference plot determine if a difference
between a CTC baseline and follow-up value is a significant increase,
a significant decrease or an insignificant change. Based on these three
categories, groups A, B and C can be established corresponding to
groups 1, 2, 3 and 4 defined by the 5 CTC cut-off: Group A: Baseline
CTC(C1) = 0 + insignificant change; Gr.B: Baseline CTC(C1) N 0 +
significant decrease; Gr.C: CTC(C3) N 0 + insignificant change or
significant increase (Figure 1).
CTC analyses
CellSearch CTC analyses on n = 47 patients at both C1 and C3
were done on replicate 7.5 ml whole blood samples collected from the
same vein puncture in 9 ml CellSave tubes (Janssen) and analyzed
within a mean of 43 hours, range [3–100 h]. Due to technical issues,
three replicate samples were scanned after up to 100 hours instead of
the recommended 96 hours. The replicate samples were reported as
mean of the two samples in the unit CTC/7.5 ml blood except when
using the individual replicate sampling to calculate CV%(dd) for
SCV-limits (Equation 3).
The CTC analyses were carried out on the CellSearch System
(formerly owned by Veridex, now Janssen). Assumed CTC were
quantified using the FDA approved CellSearch Epithelial Cell Kit, ref
7900000, Janssen based on immunomagnetic enrichment of cells of
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Figure 1. Difference plot for follow-up CTC as a function of follow-up (C3) minus baseline values (C1). Group A: (overlapping zero values
shown stacked in the plot) Patients with mean baseline CTC(C1) = 0 + insignificant change; Gr.B: CTC(C1) N 0 + significant decrease; Gr.
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(EpCAM). Positive identification of suspected CTC was done by
staining with phycoerythrin (PE) conjugated antibodies specific for
cytokeratins 8, 18, and 19 and an associated DAPI stained nuclei.
Residual leucocytes with positive DAPI were negatively discriminated
by anti-CD45 antibodies conjugated with allophycocyanin (APC).
All CTC evaluations after the Veridex criteria were performed by a
single certified operator to avoid inter analyst variation [17].
Statistics
The main objective was to assess the ability of Gr1234 and GrABC to
predict an effect of chemotherapy based on baseline and follow-up values
of CTC in 7.5 ml of blood. Gr1234 used the cut-off of 5 CTC/7.5 ml as
grouping parameter for treatment response and GrABC used SCV-limits
to identify a significant change as grouping parameter. Kaplan-Meier PFS
and OS curves for the groups were compared using log-rank test. All
statistics were done using STATA11, StataCorp.
Results
The 47 patients enrolled had a mean age of 59.5 with a range of 30 to
81 years. A total of 12 deaths (26%) and 29 patients with disease
progression (62%) were registered. Of the 29 patients with disease
progression, 6 changed therapy or died before follow-up leaving n =
23 with disease progression evaluable for treatment effect. At baseline
mean values of CTC replicate samples showed n = 34 had CTC ≥1/
7.5 ml (72%) and n = 22 had CTC ≥5 (47%).
Prognostic value of 5 CTC cut-off at baseline
Stratifying the patients’ CTC values at baseline according to the
classic prognostic cut-off of 5 CTC for worsened PFS and OS [1]
showed no significant difference in OS (P = .975) for patients with
CTC above and below 5 (Figure 2A). Similarly for PFS no difference(P = .887) between patients with CTC values above and below cut-off
was found as illustrated by a median PFS(CTC b5) = 183 days and
median PFS(CTC ≥5) = 171 days (Figure 2B).
Prognostic value of 5 CTC cut-off at follow-up
Stratifying the patients’ CTC values at follow-up according to the
classic prognostic cut-off of 5 CTC still resulted in non-significant
difference for OS (Figure 2C, P = .170). In contrast there was a
significant difference in PFS (P b .001) between patients with CTC
values above and below the 5 CTC/7.5 ml cut-off (Figure 2D) after
the administration of two cycles of chemotherapy.
Treatment effect
Median CTC values at baseline were 4 CTC/7.5 ml blood with
95% confidence interval [1.5-12.7], mean = 353 CTC/7.5 ml blood
and range [0–13.803] (Figure 3). After two cycles of chemotherapy
the median CTC value fell to 0 with 95%CI [0–0.5], mean = 6.4
CTC/7.5 ml and range [0–149] (Figure 3).
Two approaches for evaluation of the effect of chemotherapy were
evaluated in this study. The Gr1234 approach used the cut-off of 5
CTC/7.5 ml as grouping parameter for treatment response. The new
approach GrABC used SCV-limits to identify a significant change as
grouping parameter by taking the analytical variation of the CellSearch
method into account when assessing a difference between baseline and
follow-up. For the present patient cohort, the GrABC grouping
parameter was illustrated in the difference plot Figure 1. The classic
Gr1234 grouping parameters [12,13] are illustrated in Figure 3.
Figure 3 showed that Gr1234 had n = 22 patients (47%) in the low
risk group 1 with CTC b5 at C1 and CTC b5 at C3. Group 2 had
n = 12 (25%) at medium risk with CTC ≥5 at C1 and drop to CTC
b5 at C3. The high risk group 4 with CTC ≥5 at both C1 and C3
includes n = 5 (11%) of the patients. No patients fell into group 3
Mean CTC(C3)<5 Mean CTC(C3)>=5
PFS Follow-up (C3)  mean CTC of 2x7.5 ml blood
3314
2
4
11
15 9
65 19
31
22
28
13
8
321 7
20
25
29
17
24
P< 0.001
0.
00
0.
25
0.
50
0.
75
1.
00
Mean CTC(C1)<5 Mean CTC(C1)>=5
OS follow-up (C3) mean CTC of 2x7.5 ml blood
0 100 200 300 400 500
Analysis time (days)
Mean CTC(C1)<5 Mean CTC(C1)>=5
OS Baseline (C1) mean CTC of 2x7.5 ml blood
P=0.975
A
1012 36
44
1428
5
19
18
15
24
1
P=0.170
C
51
24
15
1928
14
0.
00
0.
25
0.
50
0.
75
1.
00
0.
00
0.
25
0.
50
0.
75
1.
00
0 100 200 300 400 500
Analysis time (days)
Mean CTC(C1)<5 Mean CTC(C1)>=5
PFS Baseline (C1) mean CTC of 2x7.5 ml blood
P=0.887
B
8
7 11
1
10
31
2
4
19
12
2928
6 24
1513
22
9
32
5
26
20
33
14
17
25
0.
00
0.
25
0.
50
0.
75
1.
00
18
36 44
D
0 100 200 300 400 5000 100 200 300 400 500
Analysis time (days)Analysis time (days)
Figure 2. Kaplan-Meier plots for overall survival and progression free survival at baseline (A and B) and at follow-up (C and D). Red curves
represent patients with mean CTC values of two 7.5 ml blood samples with CTC ≥5 and green curves represent patients with CTC b5.
14 27 31 
13 32 37 40
32 33 34 37 39
5 19 30 42 45
2 4 5 9 22 30 31
9
2 4 15 22
15
43
46
46
11
29
29
13
47
14 1944
35
16
27
17
17
3
6
38
38
12
36
41
1
1
8
8
23
18
24
24
2525
26
28 28
7
3 6 7
33 34 39
11 16 20 21 35
10
21
42 43 45 47 40 
20
0
1
10
100
1000
10000
100000 Gr. 1: C1<5 / C3<5              (n=22)
Gr. 2: C1≥5 / C3<5              (n=12)
Gr. 3: C1<5 / C3≥5  (n=0)
Gr. 4: C1≥5 / C3≥5  (n=5)
Dead before C3 (n=3)
Changed chemo before C3 (n=5)
C1 = C3
C1 > C3
C1 < C3
Baseline (C1) Follow-up (C3)
M
ea
n 
CT
C/
7.
5 
m
l b
lo
od
5 CTC
Figure 3. Logarithmic plot of replicate CTC mean values at baseline (C1) for n = 47 patients and at follow-up (C3) for n = 39 patients.
Each line represents CTC development for a patient (ID in small numbers) and was grouped in accordance with the shown Gr1234
grouping approach.
698 Treatment Effect in cancer using new CTC approach Horn et al. Translational Oncology Vol. 7, No. 6, 2014
0 100 200 300 400 500
Analysis time (days)
Gr.1: C1<5;   C3<5 (At risk: 27 30 31 37 39 40 42 43 45 47)
Gr.2: C1>=5; C3<5 (At risk: 3 16 21 35 38 46)
Gr.4: C1>5;   C3>5 (At risk: No patients)
20
6
1
7
11
8
15 13
9
33
14
5 19
32
2
22
31
4
28
29
25
17
24A
Gr.3: C1<5 CTC; C3>=5CTC (No patients) 
0.
00
0.
25
0.
50
0.
75
1.
00
0 100 200 300 400 500
Analysis time (days)
Gr.A C1=0, No significant change (At risk: Patient 34 39)
Gr. B: C1>0, Sign. decrease (At risk: 3 16 21 30 35 37 38 40 41 42 43 45 46 47)
Gr. C: C3>=0, No significant change
6
29
9 20
5
11
8
33
3132
1
2
7
24
22
425
19
15
28
13
14
B
17
0.
00
0.
25
0.
50
0.
75
1.
00
Or significant increase (At risk: Patient 27) 
PF
S
PF
S
Gr A B C D: p=0.032
Gr    B C    : p=0.009
Gr 1    4:  p=0.013
Gr 1 2 3 4 :  p>0.001
Gr 1 2        :  p=0.058
Gr    2   4:  p>0.001
Figure 4. N = 23 patients with progressive disease who had both C1 and C3 values at the end of the study. Progression free survival
curves for (A) risk group 1, 2, 3 and 4 assessed by the Gr1234 approach using 5 CTC cut-off as a grouping parameter for treatment effect;
(B) risk groups A, B and C assessed by the GrABC approach using the significant change values limits as grouping parameter for treatment
effect. The approaches are elaborated in the method section. Small pitch figures indicate patient ID number.
Translational Oncology Vol. 7, No. 6, 2014 Treatment Effect in cancer using new CTC approach Horn et al. 699defined by low baseline CTC(C1) ≤5 and increased CTC(C3) ≥5 at
follow-up and n = 8 (17%) patients died or changed treatment before
follow-up.
The GrABC approach generated groups from the difference plot
Figure 1. Accordingly the expected low risk group A counts n = 4
patients (9%) with CTC = 0 at C1 and no change at C3. Group B
encompasses n = 27 (57%) at expected medium risk with CTC(C1)
N0 and a significant decrease in the CTC value at C3 compared to the
CTC(C1) value. Group C had n = 8 (17%) patients with an expected
high risk due to a value of CTC(C3) N0 and no significant change or
a significant increase in CTC value from C1 to C3 samples (Figure 1).
Treatment effect with respect to PFS
The Gr1234 groups and the GrABC groups were plotted in PFS
Kaplan-Meyer plots (Figure 4). N = 39 patients had both baseline
and follow-up CTC values for evaluation and n = 23 patients
experienced disease progressions before the end of the study. OS
Kaplan-Meyer is not shown as only n = 8 of 12 registered deaths had
follow-up values. When stratified among 3 or 4 risk groups, 8 patients
could not provide valid data.
Risk groups 1, 2 and 4 generated by the Gr1234 approach had a
significantly different (P N .001) progression free survival (Figure 4A)
using the 5 CTC cut-off as a grouping parameter for treatment effect.
It was of note that the expected low risk group 1 had shorter median
PFS (244 days) than the expected medium risk group 2 (414 days).
The low risk group 1 generated by Gr1234 (green curve Figure 4A)
was identical to the low risk group 1 (green curve Figure 2B) except
for patients 10 and 44 who changed therapy before follow-up. Also
the high risk group for Gr1234 approach (Figure 4A, red curve) and
the high risk group for CTC(C3) ≥5 at follow-up (Figure 2D, red
curve) were identical. It follows that group 2 in Figure 4A generated
by the Gr1234 approach was extracted from the high risk group CTC
(C1) ≥5 (Figure 2B, red curve) by identifying patients 20, 6, 1, 7 11
and 8 who were responding to therapy and dropped at follow-up to
CTC(C3) b5 after two cycles of chemotherapy.
The GrABC approach generated three risk groups A, B and C
also with a significant separation (P = .032) of the groups using
significant change values limits as grouping parameter for
treatment effect according to PFS (Figure 4B). There was anunequal distribution of patients in groups A, B, and C which
affects the level of significance.
Higher risk groups by GrABC
Among the n = 23 patients with disease progression, the GrABC
approach upgraded 10 patients to a higher risk group and downgraded
the risk groups of 2 patients compared to the grouping obtained with
the current Gr1234 approach. The two approaches agreed on the risk
groups for 11 patients. The different grouping of the patients by the
Gr1234 and GrABC approaches are visualised in Figure 4A versus B.
For the patients with disease progression, 8 patients were placed in
the high risk group C by the GrABC approach compared to 5 patients
placed in the high risk group 4 by the Gr1234 approach. GrABC
agrees on three of these high risk patients (24, 25 and 28),
but downgrades the risk group to medium risk B for two patients
17 and 29. In contrast four patients [13–15,19] were upgraded to
the high risk group C (Figure 4B) from the Gr1234 approach low
risk group 1 (Figure 4A).
Likewise the GrABC approach upgraded 6 patients to the medium risk
group B (Figure 4B) from the Gr1234 approach low risk group 1
(Figure 4A). Only 2 patients were left in the low risk group A. compared to
Gr1234 that places 12 of the progressed patients in the low risk group 1.
Figure 4A shows that low risk group 1 unexpectedly has a shorter median
PFS (244 days) compared to the medium risk group 2 (414 days). The
GrABC approach achieves amedian PFS of 303 days for the low risk group
A and 284 days for the medium risk group B by upgrading the risk group
for all patients in the low risk group 1 (Figure 4A), except patients 31 and
33, to the medium risk group B (Figure 4B).
Discussion
In this study we proposed a new GrABC approach using the SCV-
limits as grouping parameter for treatment effect. The main objective
to compare GrABC with the existing approach Gr1234 and evaluate
their grouping ability in terms of PFS both showed significant
correlations. For GrABC P = .032 and for Gr1234 P N .001.
Statistically stronger P values by the Gr1234 approach could be
attributed to the even distribution of patients in the three groups
compared to the uneven distribution of patients in the three groups
by the GrABC approach (Figure 4A and B). Both Gr1234 and
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groups (Groups A/1), expected responders to chemotherapy (Groups
B/2) and expected non responders (Groups C, 3 and 4).
GrABC upgraded risk for CTC(C1) b5 and CTC(C3) b5
Using SCV-limits the GrABC approach had the ability to utilize
the low values below 5 CTC. Patients 13, 14, 15 and 19 had low
CTC values b5 at all times making them a low risk group 1 in the
Gr1234 approach (Figure 3). But the GrABC approach classified
these patients as medium risk group 3 (or C) due to an insignificant
change of the low baseline CTC value (Figure 1). This increased risk
group by the GrABC approach was in accordance with the relatively
short time to progression observed for patients 13, 14, 15 and 19 and
death for patients 14, 15, 19 (Figures 2 and 4).
GrABC downgraded risk for CTC(C3) ≥5
Both approaches categorize the numeric CTC values into low risk
groups, expected responders to chemotherapy and expected non
responders. By loss of quantitative CTC values, valuable prognostic
information is lost as reported by several authors who showed a non
linear increase in risk of both progression and death with increasing
number of CTC [14,21,22].This poses a potential problem for the
GrABC approach since patients that progressed like patients 17 and
29 experienced a significant decrease from baseline to follow-up and
ended up in the medium risk group B, but still had a follow-up CTC
≥5. By the Gr1234 approach patients 17 and 29 were categorized in
the high risk group 4 (Table 3). According to GrABC and the
hypothesis the CTC in patients 17 and 29 were responding to the
chemotherapy even though their follow-up CTC(C3) ≥5 was
associated with poor prognosis. Patients 17 and 29 had progressed
but were still alive, and the hypothesis was supported by patient 38
who had also experienced a significant decrease from baseline to a
follow-up CTC(C3) = 4 and was alive at the end of the study period
without progression. More data are required to verify the hypothesis.
SCV intervals
The intervals [0–4], [5–20], [20–∞] used for construction of the
SCV-limits in the difference plot (Figure 1) were adopted from
Botteri et al. who showed increase in risk of both progression and
death with increasing numbers of CTC [22]. These intervals were
implemented for the SCV-limits to limit the impact of the biological
variation on CTC in the mBC patient cohort. The biological
variation between subjects ranged between 0–13.808 CTC/7.5 ml in
the present study. Ranges from 0–23.618 CTC/7.5 ml have been
reported [5,12]. A range of this magnitude would introduce a total
variation (Equation 2) so wide that SCV-limits (Equation 4) would be
useless to detect small differences between baseline and follow-up.
Also the analytical variation differed when counting replicate samples
containing 5 CTC/7.5 ml or 50 CTC/7,5 ml blood [5]. A tendency
towards high CTC values for the mastitis BC subtype was observed.
Furthermore the different levels of CTC can be associated with
different BC subtype [23]. Therefore it seemed eligible to construct
SCV-limits in intervals due to both analytical and clinical arguments.
Total CTC in 15 ml blood samples
The study could have been based on a total of 15 ml blood samples
due to the replicate samples for assessing analytical variation of the
CellSearch System. Increased blood volume could have increased the
sensitivity of the analysis according to Coumans et al. [21].Unexpectedly the use of total CTC in 15 ml blood gave a statistically
reduced separation (P = 0.025, plot not shown) of groups 1, 2 and 4
similar to Figure 4A for the Gr1234 approach. The use of total CTC
in 15 ml did not change the distribution of patients in the groups for
the GrABC approach, since it is based on differences (Figure 1). The
mean values of the 2×7.5 ml were therefore chosen and it also
facilitates comparison with other studies.
Prognostic value of CTC ≥5 at baseline with respect to
OS and PFS
In a large study, Pierga et al. found that 65% had CTC ≥1 and
44% had CTC ≥5/7.5 ml in mBC patients measured with the
CellSearch System [6]. Our rates of 72% and 47% are in accordance
with these findings, given that Pierga et al. only enrolled patients in
1st line of therapy. The prognostic value of CTC ≥5 CTC/7.5 ml at
baseline has repeatedly been confirmed [1,6,14,24]. This study could
not validate the prognostic value of CTC(C1) ≥5 for OS or PFS. This
could be due to a lack of power linked to progression data from only
n = 23, shorter median follow-up time or, as indicated by the crossing
of the Kaplan-Meier curves (Figure 2B), an interaction possibly due to
a patient cohort in worse condition than the other study cohorts.
The difference in the patients’ condition is illustrated in Figure 4A
where the green risk group 1 had unexpectedly longer median PFS
compared to the blue medium risk group 2. All six patients in group 2
were in 1st line treatment which could lessen their risk of progression
compared to group 1 where only 5 of 13 (38%) patients were in 1st line
therapy while 62% were in an advanced line of therapy. More patients
with different lines of therapy in the cohort could balance this issue.
Prognostic value of CTC ≥5 at follow-up with respect to
OS and PFS
At follow-up a significant difference in PFS (P b .001) between the
groups above and below 5 CTC/7.5 ml was shown (Figure 2D) in
concordance with Cristofanilli et al. [13]. This was expected as the
two cycles of chemotherapy have split the red high risk PFS curve at
baseline with CTC ≥5 (Figure 2B) into the expected medium risk
group 2 responders with CTC(C3) b5 (blue curve, Figure 4A) and
expected high risk group 4 non-responders with CTC(C3) ≥5) (red
curve, Figure 4A) by means of the Gr1234 approach. The Figure 4A
low risk group 1 (green) and medium risk group 2 (blue) of the
Gr1234 approach were again merged into the green PFS curve in
Figure 2D representing low risk CTC(C3) b5 leaving the red high
risk PFS curves of Figures 2D and 4A identical. Given that the red
curve (high risk group CTC ≥5) in Figure 2B was comprised of risk
groups 2 and 4 (Figure 4A), the curves in Figure 2B would possibly be
more separated if group 2 had the expected shorter median PFS than
group 1 (Figure 4A).
At follow-up the OS for patients above and below 5 CTC cut-off
had only two patients in the high risk group with CTC ≥5
(Figure 2C) and is not statistically valid.
The challenge of the 5 CTC cut-off
Coumans et al. made a large retrospective study on interpreting
changes in circulating tumour cell count on a cohort of cancer
patients all with baseline ≥5 CTC/7.5 ml [21]. They challenged the
static cut-off of 5 CTC by using the Poisson distributed nature of
CTC in blood samples to set up probability percentage based criteria
for a CTC reduction. Unfortunately they sat the limit at 99.9% due
to statistical reason and found this approach less adequate compared to
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probability approach is incomparable to the SCV-limits used in the
present study (data not shown). An advantage of the GrABC approach
is that the Poisson distributed nature of CTC is part of the analytical
variation of the true replicate samples from the same vein puncture.
Our proposed GrABC approach gives the clinician well defined
SCV-limits to identify changes in repeated measurements. SCV-
limits are already used for clinical purposes in algorithms for
management of anticoagulant treatment operating in a narrow
therapeutic interval [19]. The SCV-limits presented here hold true for
a broad metastatic setting of BC patients with mixed lines of treatment
and a single operator for CTC evaluation using a CellSearch System
with similar analytical variation. Applying the SCV-limits retrospec-
tively on a larger patient cohort could provide solid data to determine
the value of the GrABC approach for simple and more factual
interpretation of changes in CTC for treatment effect.
Conclusion
We propose a new approach to evaluate treatment effect using SCV-
limits to interpret significant changes in mBC patients’ baseline and
follow-up CTC values. The SCV guided approach for grouping
patients in favourable or unfavourable risk groups correlated with PFS
(P = .032). The existing approach based on a 5 CTC cut-off for
grouping high and low risk patients correlated with PFS (P N .001),
but inverted the expected PFS time for the low and medium risk
groups in this cohort. More patients are needed to balance the size of
the groups for better comparison and hence to demonstrate the
possible benefit of using SCV-limits to interpret significant changes in
CTC as a predictive factor for treatment effect in mBC.
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